ABL Biotech is setting up a 100 crore facility to manufacture DHA and EHA at the Marine Biotech Park at Visakhapatnam. It would be the World's 2nd India's 1st DHA, EHA facility.

The AP Government has developed a Marine Biotech Park in Visakhapatman, India modeled on the lines of SP Biotech Park of Genome valley. One of its first occupents, Celgen Biologicals Pvt Ltd (Celgen), a wholly owned subsidiary of ABL Biotechnologies, is in the process of establishing India's first facility for the production of the essential fatty acid DHA at Visakhapatnam.

It has been one of the first companies to be allotted ten acres of land in the Marine Biotech Park at Visakhapatnam. According to the officials of Celgen, in spite of ABL Biotechnologies operations being based out of Chennai, it has looked at putting up the Celgen project in AP on the basis of development and support in that state. Celgen focuses at microbial metabolites that have commercial use.

It was set with the objective of establishing a global presence in the area of phytopharmaceuticals from original research conducted in various parts of the world, especially India. The technology for this project has been sourced from ABL Biotechnologies. This project would be the first of its kind in India and second in the world for the production of Omega Fatty acids from plant sources. Celgen would be investing about Rs 100 crore in this area. It proposes to produce around 100 MT of DHA per annum.